UTI

SEC source: 0001261654-20-000057 · wf-form4_160046071328595.xml · nonDerivative · entry 3

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,823

F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F4 · price: The shares were sold at prices ranging from $6.535 to $6.740. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001261654-20-000055 · wf-form4_160037824599546.xml · nonDerivative · entry 1

Smith Sherrell · CIK 0001371105 · EVP, Campus Ops & Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,076

F1 · shares: Vesting of Restricted Stock granted on 9/14/2016. Shares withheld to satisfy tax liability.

SEC source: 0001261654-20-000057 · wf-form4_160046071328595.xml · nonDerivative · entry 2

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 239,823

F2 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F3 · price: The shares were sold at prices ranging from $6.55 to $6.71. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001261654-20-000057 · wf-form4_160046071328595.xml · nonDerivative · entry 1

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 279,823

F1 · shares: Vesting of Restricted Stock granted on 9/14/2016. Shares withheld to satisfy tax liability.

SEC source: 0001261654-20-000047 · wf-form4_160021239764651.xml · nonDerivative · entry 1

Severson Eric · CIK 0001746556 · SVP Admissions

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,102

F1 · shares: Vesting of Restricted Stock Units granted on 9/12/2018. Shares withheld to satisfy tax liability.

SEC source: 0001261654-20-000049 · wf-form4_160029028218392.xml · nonDerivative · entry 2

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 297,953

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F3 · price: The shares were sold at prices ranging from $6.500 to $6.715. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the numberof shares sold at each separate price.

SEC source: 0001261654-20-000053 · wf-form4_160037799600727.xml · derivative · entry 2

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,248

Underlying: Common Stock, $0.0001 par value · 21,248 shares

Expires 2022-09-15

F2 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F2 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001261654-20-000053 · wf-form4_160037799600727.xml · nonDerivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,332

F1 · shares: One third of the restricted stock units approved by the Board of Directors shall vest on each anniversary of the grant date.

SEC source: 0001261654-20-000051 · wf-form4_160037767319446.xml · derivative · entry 2

Mason Sonia Claire · CIK 0001821986 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,793

Underlying: Common Stock, $0.0001 par value · 10,793 shares

Expires 2022-09-15

F2 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F2 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001261654-20-000051 · wf-form4_160037767319446.xml · nonDerivative · entry 1

Mason Sonia Claire · CIK 0001821986 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,756

F1 · shares: One third of the restricted stock units approved by the Board of Directors shall vest on each anniversary of the grant date.

SEC source: 0001261654-20-000093 · wf-form4a_160875875692799.xml · derivative · entry 1

Fesperman Bart · CIK 0001821616 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,270

Underlying: Common Stock, $0.0001 par value · 11,332 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of UTI Common Stock.

F2 · shares: This Form 4/A does not report a new transaction. The reporting person's original Form 4 incorrectly reported these securities as Common Stock rather than restricted stock units.

F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on September 15, 2021.

F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on September 15, 2021.

F4 · balance_after: The incorrect classification described in footnote (2) above resulted in incorrect reporting of beneficial ownership of the UTI Common Stock in the original Form 4. As of the date of this Form 4/A, none of the restricted stock units has vested. The beneficial ownership of the restricted stock units has been corrected in this Form 4/A and reflects the reporting person's correct ownership as of the date of this filing.

SEC source: 0001261654-20-000091 · wf-form4a_160875842571639.xml · derivative · entry 1

Mason Sonia Claire · CIK 0001821986 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,694

Underlying: Common Stock, $0.0001 par value · 5,756 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of UTI Common Stock.

F2 · shares: This Form 4/A does not report a new transaction. The reporting person's original Form 4 incorrectly reported these securities as Common Stock rather than restricted stock units.

F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on September 15, 2021.

F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on September 15, 2021.

F4 · balance_after: The incorrect classification described in footnote (2) above resulted in incorrect reporting of beneficial ownership of the UTI Common Stock in the original Form 4. As of the date of this Form 4/A, none of the restricted stock units has vested. The beneficial ownership of the restricted stock units has been corrected in this Form 4/A and reflects the reporting person's correct ownership as of the date of this filing.

SEC source: 0000899243-20-025337 · doc4.xml · derivative · entry 1

Coliseum Capital Management, LLC · CIK 0001409751 · Director · 10% owner

Shackelton Christopher S · CIK 0001430708 · Director · 10% owner

Coliseum Capital, LLC · CIK 0001409585 · Director · 10% owner

COLISEUM CAPITAL PARTNERS, L.P. · CIK 0001356974 · Director · 10% owner

Coliseum Capital Partners II, L.P. · CIK 0001567187 · Director · 10% owner

Coliseum Holdings I, LLC · CIK 0001678188 · Director · 10% owner

Coliseum Capital Co-Invest, L.P. · CIK 0001572285 · Director · 10% owner

Gray Adam · CIK 0001454123 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 444,944

Underlying: Common Stock · 7,659,339 shares

Expires not disclosed

F1 · derivative.exercise_price: The conversion rate in effect at any applicable time for conversion of each share of Series A Preferred Stock into common stock will be the quotient obtained by dividing the liquidation preference then in effect by the conversion price then in effect, plus cash in lieu of fractional shares. The initial liquidation preference is $100 per share and the initial conversion price is $3.33 per share.

F2 · derivative.exercise_date: When issued, the Series A Preferred Stock was immediately exercisable with respect to 1,214,791 shares of the Issuer's common stock (the "Common Shares"). The Series A Preferred Stock was convertible into 19,806,230 additional Common Shares only after Regulatory Approval (as such term is defined in the Certificate of Designations of the Series A Preferred Stock) has been obtained. The Series A Preferred Stock has no expiration date.

F3 · derivative.exercise_date: (Continued from Footnote 2) On September 14, 2020, Coliseum Holdings I LLC ("CHI"), the record owner of all 700,000 shares of Series A Preferred Stock of UTI (the "Preferred Shares") distributed the Preferred Shares to its four members, (a) Coliseum Capital Partners, L.P. ("CCP"), an investment limited partnership of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser, (b) Coliseum Capital Partners II, L.P. ("CCP2"), an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, (c) Coliseum Capital Co-Invest, L.P. ("CCC" and, together with CCP and CCP2, the "Funds") and (d) a separate account investment advisory client of CCM (the "Separate Account").

F4 · derivative.exercise_date: (Continued from Footnote 3) Following this distribution, CCP2 and CCC distributed the Preferred Shares they received to their respective limited partners. We refer to these distributions as the "Distributions." Mr. Gray and his spouse, trusts established for the benefit of Mr. Gray's descendants, Mr. Shackleton, and trusts established for the benefit of Mr. Shackleton's descendants received Preferred Shares from each of CCP2 and CCC in their capacities as limited partners thereof.

F5 · derivative.exercise_date: (Continued from Footnote 4) Prior to the Distributions, CCM had voting and investment control over certain securities owned in the Separate Account. In connection with the Distribution, CCM and the client owner of the Separate Account amended the investment management account (the "Investment Management Account Amendment") to eliminate voting and dispositive authority over 56,000 shares of Series A Preferred Stock of UTI. As a result, the Reporting Persons disclaim beneficial ownership of such securities. Pursuant to the Investment Management Account Amendment, CCM retains voting and dispositive authority over 75,320 shares of Series A Preferred Stock of UTI held in the Separate Account.

F6 · derivative.exercise_date: (Continued from Footnote 5) Following the Distributions and the Investment Management Account Amendment, Mr. Gray and his trusts held 10,162 Preferred Shares; Mr. Shackleton and his trusts held 10,162 Preferred Shares; CCP held 349,300 Preferred Shares and the Separate Account held 75,320 Preferred Shares that are reported herein.

F7 · derivative.exercise_date: (Continued from Footnote 6) The Board of Directors of the Issuer has determined that, following the Distributions, as to the shares of Series A Preferred Stock held by the Reporting Persons, no Regulatory Approval is required prior to the Reporting Persons (A) converting a number of shares of Series A Preferred Stock into common stock provided that the number of shares of common stock issued pursuant to such conversion, in the aggregate, is less than or equal to 9.9% of the number of shares of common stock outstanding on an as converted basis on the date of the Distributions, and (B) voting a number of shares of Series A Preferred Stock provided that the voting power of such shares of Series A Preferred Stock and any shares of common stock issued upon conversion of such shares of Series A Preferred Stock is less than or equal to 9.9% of the voting power of the common stock on the date of the Distributions (the foregoing limitations, the "Continuing Caps").

F8 · derivative.exercise_date: (Continued from Footnote 7) Regulatory Approval will continue to be required for, and the Continuing Caps will remain in place with respect to, the shares of Series A Preferred Stock acquired by the Reporting Persons in the Distributions to the extent such shares, on an as converted basis, represent in excess of 9.9% of the Company's common stock and voting power as of the date of the Distributions.. The remaining shares of Series A Preferred Stock held by the Reporting Persons, which would be convertible into 8,052,142 Common Shares, remain subject to the Continuing Caps, and may not be converted or voted without receipt of Regulatory Approval or a further good faith determination by UTI that such Regulatory Approval is not required. The Reporting Persons have the right to request that such approval or a good faith determination that such approval is not required at any time.

F2 · derivative.expiration_date: When issued, the Series A Preferred Stock was immediately exercisable with respect to 1,214,791 shares of the Issuer's common stock (the "Common Shares"). The Series A Preferred Stock was convertible into 19,806,230 additional Common Shares only after Regulatory Approval (as such term is defined in the Certificate of Designations of the Series A Preferred Stock) has been obtained. The Series A Preferred Stock has no expiration date.

F3 · derivative.expiration_date: (Continued from Footnote 2) On September 14, 2020, Coliseum Holdings I LLC ("CHI"), the record owner of all 700,000 shares of Series A Preferred Stock of UTI (the "Preferred Shares") distributed the Preferred Shares to its four members, (a) Coliseum Capital Partners, L.P. ("CCP"), an investment limited partnership of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser, (b) Coliseum Capital Partners II, L.P. ("CCP2"), an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, (c) Coliseum Capital Co-Invest, L.P. ("CCC" and, together with CCP and CCP2, the "Funds") and (d) a separate account investment advisory client of CCM (the "Separate Account").

F4 · derivative.expiration_date: (Continued from Footnote 3) Following this distribution, CCP2 and CCC distributed the Preferred Shares they received to their respective limited partners. We refer to these distributions as the "Distributions." Mr. Gray and his spouse, trusts established for the benefit of Mr. Gray's descendants, Mr. Shackleton, and trusts established for the benefit of Mr. Shackleton's descendants received Preferred Shares from each of CCP2 and CCC in their capacities as limited partners thereof.

F5 · derivative.expiration_date: (Continued from Footnote 4) Prior to the Distributions, CCM had voting and investment control over certain securities owned in the Separate Account. In connection with the Distribution, CCM and the client owner of the Separate Account amended the investment management account (the "Investment Management Account Amendment") to eliminate voting and dispositive authority over 56,000 shares of Series A Preferred Stock of UTI. As a result, the Reporting Persons disclaim beneficial ownership of such securities. Pursuant to the Investment Management Account Amendment, CCM retains voting and dispositive authority over 75,320 shares of Series A Preferred Stock of UTI held in the Separate Account.

F6 · derivative.expiration_date: (Continued from Footnote 5) Following the Distributions and the Investment Management Account Amendment, Mr. Gray and his trusts held 10,162 Preferred Shares; Mr. Shackleton and his trusts held 10,162 Preferred Shares; CCP held 349,300 Preferred Shares and the Separate Account held 75,320 Preferred Shares that are reported herein.

F7 · derivative.expiration_date: (Continued from Footnote 6) The Board of Directors of the Issuer has determined that, following the Distributions, as to the shares of Series A Preferred Stock held by the Reporting Persons, no Regulatory Approval is required prior to the Reporting Persons (A) converting a number of shares of Series A Preferred Stock into common stock provided that the number of shares of common stock issued pursuant to such conversion, in the aggregate, is less than or equal to 9.9% of the number of shares of common stock outstanding on an as converted basis on the date of the Distributions, and (B) voting a number of shares of Series A Preferred Stock provided that the voting power of such shares of Series A Preferred Stock and any shares of common stock issued upon conversion of such shares of Series A Preferred Stock is less than or equal to 9.9% of the voting power of the common stock on the date of the Distributions (the foregoing limitations, the "Continuing Caps").

F8 · derivative.expiration_date: (Continued from Footnote 7) Regulatory Approval will continue to be required for, and the Continuing Caps will remain in place with respect to, the shares of Series A Preferred Stock acquired by the Reporting Persons in the Distributions to the extent such shares, on an as converted basis, represent in excess of 9.9% of the Company's common stock and voting power as of the date of the Distributions.. The remaining shares of Series A Preferred Stock held by the Reporting Persons, which would be convertible into 8,052,142 Common Shares, remain subject to the Continuing Caps, and may not be converted or voted without receipt of Regulatory Approval or a further good faith determination by UTI that such Regulatory Approval is not required. The Reporting Persons have the right to request that such approval or a good faith determination that such approval is not required at any time.

F2 · ownership.nature: When issued, the Series A Preferred Stock was immediately exercisable with respect to 1,214,791 shares of the Issuer's common stock (the "Common Shares"). The Series A Preferred Stock was convertible into 19,806,230 additional Common Shares only after Regulatory Approval (as such term is defined in the Certificate of Designations of the Series A Preferred Stock) has been obtained. The Series A Preferred Stock has no expiration date.

F3 · ownership.nature: (Continued from Footnote 2) On September 14, 2020, Coliseum Holdings I LLC ("CHI"), the record owner of all 700,000 shares of Series A Preferred Stock of UTI (the "Preferred Shares") distributed the Preferred Shares to its four members, (a) Coliseum Capital Partners, L.P. ("CCP"), an investment limited partnership of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser, (b) Coliseum Capital Partners II, L.P. ("CCP2"), an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, (c) Coliseum Capital Co-Invest, L.P. ("CCC" and, together with CCP and CCP2, the "Funds") and (d) a separate account investment advisory client of CCM (the "Separate Account").

F4 · ownership.nature: (Continued from Footnote 3) Following this distribution, CCP2 and CCC distributed the Preferred Shares they received to their respective limited partners. We refer to these distributions as the "Distributions." Mr. Gray and his spouse, trusts established for the benefit of Mr. Gray's descendants, Mr. Shackleton, and trusts established for the benefit of Mr. Shackleton's descendants received Preferred Shares from each of CCP2 and CCC in their capacities as limited partners thereof.

F5 · ownership.nature: (Continued from Footnote 4) Prior to the Distributions, CCM had voting and investment control over certain securities owned in the Separate Account. In connection with the Distribution, CCM and the client owner of the Separate Account amended the investment management account (the "Investment Management Account Amendment") to eliminate voting and dispositive authority over 56,000 shares of Series A Preferred Stock of UTI. As a result, the Reporting Persons disclaim beneficial ownership of such securities. Pursuant to the Investment Management Account Amendment, CCM retains voting and dispositive authority over 75,320 shares of Series A Preferred Stock of UTI held in the Separate Account.

F6 · ownership.nature: (Continued from Footnote 5) Following the Distributions and the Investment Management Account Amendment, Mr. Gray and his trusts held 10,162 Preferred Shares; Mr. Shackleton and his trusts held 10,162 Preferred Shares; CCP held 349,300 Preferred Shares and the Separate Account held 75,320 Preferred Shares that are reported herein.

F7 · ownership.nature: (Continued from Footnote 6) The Board of Directors of the Issuer has determined that, following the Distributions, as to the shares of Series A Preferred Stock held by the Reporting Persons, no Regulatory Approval is required prior to the Reporting Persons (A) converting a number of shares of Series A Preferred Stock into common stock provided that the number of shares of common stock issued pursuant to such conversion, in the aggregate, is less than or equal to 9.9% of the number of shares of common stock outstanding on an as converted basis on the date of the Distributions, and (B) voting a number of shares of Series A Preferred Stock provided that the voting power of such shares of Series A Preferred Stock and any shares of common stock issued upon conversion of such shares of Series A Preferred Stock is less than or equal to 9.9% of the voting power of the common stock on the date of the Distributions (the foregoing limitations, the "Continuing Caps").

F8 · ownership.nature: (Continued from Footnote 7) Regulatory Approval will continue to be required for, and the Continuing Caps will remain in place with respect to, the shares of Series A Preferred Stock acquired by the Reporting Persons in the Distributions to the extent such shares, on an as converted basis, represent in excess of 9.9% of the Company's common stock and voting power as of the date of the Distributions.. The remaining shares of Series A Preferred Stock held by the Reporting Persons, which would be convertible into 8,052,142 Common Shares, remain subject to the Continuing Caps, and may not be converted or voted without receipt of Regulatory Approval or a further good faith determination by UTI that such Regulatory Approval is not required. The Reporting Persons have the right to request that such approval or a good faith determination that such approval is not required at any time.

F9 · ownership.nature: Following the Distributions, Mr. Gray and his trusts held 10,162 Preferred Shares; Mr. Shackleton and his trusts held 10,162 Preferred Shares; CCP held 349,300 Preferred Shares and the Separate Account held 75,320 Preferred Shares that are reported herein.

SEC source: 0001261654-20-000049 · wf-form4_160029028218392.xml · nonDerivative · entry 1

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,953

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F2 · price: The shares were sold at prices ranging from $6.58 to $6.91. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the numberof shares sold at each separate price.

SEC source: 0001209191-20-036422 · doc4.xml · nonDerivative · entry 1

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 391,819

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F2 · price: The shares were sold at prices ranging from $7.53 to $7.68. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-035392 · doc4.xml · nonDerivative · entry 3

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,261

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person

F4 · price: The shares were sold at prices ranging from $7.50 to $7.58. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-035392 · doc4.xml · nonDerivative · entry 2

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 471,261

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person

F3 · price: The shares were sold at prices ranging from $7.50 to $7.66. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-035392 · doc4.xml · nonDerivative · entry 1

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 521,261

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person

F2 · price: The shares were sold at prices ranging from $7.50 to $7.63. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-034531 · doc4.xml · nonDerivative · entry 3

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550,810

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F4 · price: The shares were sold at prices ranging from $7.500 to $7.555. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-035016 · doc4.xml · nonDerivative · entry 1

Brochick George W. · CIK 0001807493 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,608

F1 · timeliness: The award was approved by the Compensation Committee of UTI's Board of Director's and UTI's Board of Directors on June 4, 2020.

SEC source: 0001209191-20-035623 · doc4a.xml · nonDerivative · entry 1

Brochick George W. · CIK 0001807493 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,556

F1 · price: Reflects closing price on June 4, 2020, which is the official grant date of record.

SEC source: 0001209191-20-037205 · doc4a.xml · nonDerivative · entry 1

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 377,953

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan, dated 3/13/2020, adopted by the Reporting Person.

F2 · shares: Due to a broker error, the Form 4 filed by the Reporting Person on June 4, 2020 incorrectly reported that 3,473 shares were sold that day. This amendment reflects the correct amount of shares sold on June 4, 2020.

F3 · price: The shares were sold at prices ranging from $7.500 - $7.555. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4 · balance_after: Represents the number of securities beneficially owned as of June 10, 2020 when the Rule 10b5-1 plan was completed (giving effect to all reported sales subsequent to June 4, 2020).

SEC source: 0001209191-20-034531 · doc4.xml · nonDerivative · entry 2

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 554,283

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F3 · price: The shares were sold at prices ranging from $7.50 to $7.78. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-034531 · doc4.xml · nonDerivative · entry 1

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 568,377

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F2 · price: The shares were sold at prices ranging from $7.50 to $7.52. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-033298 · doc4.xml · nonDerivative · entry 3

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 569,677

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F4 · price: The shares were sold at prices ranging from $7.50 to $7.63. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-033298 · doc4.xml · nonDerivative · entry 2

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 610,303

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F3 · price: The shares were sold at prices ranging from $7.50 to $7.58. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-20-033298 · doc4.xml · nonDerivative · entry 1

MCWATERS KIMBERLY J · CIK 0001272480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 633,923

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F2 · price: The shares were sold at prices ranging from $7.500 to $7.505. The Reporting Person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price

SEC source: 0000899243-20-014228 · doc4.xml · nonDerivative · entry 1

Coliseum Capital Management, LLC · CIK 0001409751 · Director · 10% owner

Shackelton Christopher S · CIK 0001430708 · Director · 10% owner

Coliseum Capital, LLC · CIK 0001409585 · Director · 10% owner

COLISEUM CAPITAL PARTNERS, L.P. · CIK 0001356974 · Director · 10% owner

Coliseum Capital Partners II, L.P. · CIK 0001567187 · Director · 10% owner

Coliseum Holdings I, LLC · CIK 0001678188 · Director · 10% owner

Coliseum Capital Co-Invest, L.P. · CIK 0001572285 · Director · 10% owner

Gray Adam · CIK 0001454123 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.87 to $7.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These securities were beneficially owned solely by Christopher Shackelton ("Shackelton") and consist of (a) 2,400 shares held directly by Shackelton, (b) 28,875 shares held by Shackelton's spouse and (c) 10,200 shares held by trusts for the benefit of Shackelton's descendants.

SEC source: 0001209191-20-016301 · doc4.xml · derivative · entry 2

Kevane Christopher E. · CIK 0001486632 · SVP Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,705

Underlying: Common Stock · 18,705 shares

Expires 2022-03-02

F2 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F2 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001209191-20-016301 · doc4.xml · nonDerivative · entry 1

Kevane Christopher E. · CIK 0001486632 · SVP Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,976

F1 · shares: One third of the restricted stock units approved by the Board of Directors shall vest on each anniversary of the grant date.

SEC source: 0001261654-20-000095 · wf-form4a_160875892538768.xml · derivative · entry 1

Kevane Christopher E. · CIK 0001486632 · SVP Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,754

Underlying: Common Stock, $0.0001 par value · 9,976 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of UTI Common Stock.

F2 · shares: This Form 4/A does not report a new transaction. The reporting person's original Form 4 incorrectly reported these securities as Common Stock rather than restricted stock units.

F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on March 2, 2021.

F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on March 2, 2021.

F4 · balance_after: The incorrect classification described in footnote (2) above resulted in incorrect reporting of beneficial ownership of the UTI Common Stock in the original Form 4. As of the date of this Form 4/A, none of the restricted stock units has vested. The beneficial ownership of the restricted stock units has been corrected in this Form 4/A and reflects the reporting person's correct ownership as of the date of this filing.

SEC source: 0001209191-20-013805 · doc4.xml · nonDerivative · entry 1

PENSKE ROGER S · CIK 0000942439 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,445

F1 · shares: The award was approved by the Compensation Committee of UTI's Board of Directors and UTI's Board of Directors on February 27, 2020.

SEC source: 0001209191-20-013798 · doc4.xml · nonDerivative · entry 1

WHITE JOHN C · CIK 0001272479 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,633

F1 · shares: The award was approved by the Compensation Committee of UTI's Board of Directors and UTI's Board of Directors on February 27, 2020.

SEC source: 0001209191-20-013802 · doc4.xml · nonDerivative · entry 1

TRAMMELL KENNETH R · CIK 0001239782 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,844

F1 · shares: The award was approved by the Compensation Committee of UTI's Board of Directors and UTI's Board of Directors on February 27, 2020.

SEC source: 0001209191-20-013796 · doc4.xml · nonDerivative · entry 1

DEVINCENZI ROBERT THOMAS · CIK 0001226186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,191

F1 · shares: The award was approved by the Compensation Committee of UTI's Board of Directors and UTI's Board of Directors on February 27, 2020.

SEC source: 0001209191-20-013787 · doc4.xml · nonDerivative · entry 1

Blaszkiewicz David · CIK 0001536971 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,362

F1 · shares: The award was approved by the Compensation Committee of UTI's Board of Directors and UTI's Board of Directors on February 27, 2020.

SEC source: 0001209191-20-013776 · doc4.xml · nonDerivative · entry 1

Paige Roderick R · CIK 0001368337 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,749

F1 · shares: The award was approved by the Compensation Committee of UTI's Board of Directors and UTI's Board of Directors on February 27, 2020.

SEC source: 0001209191-20-013778 · doc4.xml · nonDerivative · entry 1

LENNOX WILLIAM J JR · CIK 0001597376 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,729

F1 · shares: The award was approved by the Compensation Committee of UTI's Board of Directors and UTI's Board of Directors on February 27, 2020.

SEC source: 0001209191-20-013775 · doc4.xml · nonDerivative · entry 1

SRERE LINDA J · CIK 0001193863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,325

F1 · shares: The award was approved by the Compensation Committee of UTI's Board of Directors and UTI's Board of Directors on February 27, 2020.

SEC source: 0001209191-20-016070 · doc4.xml · nonDerivative · entry 1

DEVINCENZI ROBERT THOMAS · CIK 0001226186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,245

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.5313 to $7.6500, inclusive. The reporting person undertakes to provide to Universal Technical Institute, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-002755 · doc4.xml · derivative · entry 2

Hitchcock Todd A · CIK 0001799015 · SVP Chief Strategy & Transform

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,647

Underlying: Common Stock · 21,647 shares

Expires 2022-01-07

F2 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F2 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001209191-20-002755 · doc4.xml · nonDerivative · entry 1

Hitchcock Todd A · CIK 0001799015 · SVP Chief Strategy & Transform

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,545

F1 · shares: One third of the restricted stock units approved by the Board of Directors shall vest on each anniversary of the grant date.

SEC source: 0001209191-20-002747 · doc4.xml · derivative · entry 3

Smith Lori B · CIK 0001799017 · SVP Chief Information Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,647

Underlying: Common Stock · 21,647 shares

Expires 2022-01-07

F2 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F2 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001209191-20-002747 · doc4.xml · nonDerivative · entry 1

Smith Lori B · CIK 0001799017 · SVP Chief Information Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,206

F1 · shares: One third of the restricted stock units approved by the Board of Directors shall vest on each anniversary of the grant date.

SEC source: 0001209191-20-002751 · doc4.xml · derivative · entry 2

Severson Eric · CIK 0001746556 · SVP Admissions

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,647

Underlying: Common Stock · 21,647 shares

Expires 2022-01-07

F2 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F2 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001209191-20-002751 · doc4.xml · nonDerivative · entry 1

Severson Eric · CIK 0001746556 · SVP Admissions

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,540

F1 · shares: One third of the restricted stock units approved by the Board of Directors shall vest on each anniversary of the grant date.

SEC source: 0001209191-20-002733 · doc4.xml · derivative · entry 3

Smith Sherrell · CIK 0001371105 · EVP, Campus Ops & Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,822

Underlying: Common Stock · 33,822 shares

Expires 2022-01-07

F2 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F2 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001209191-20-002733 · doc4.xml · nonDerivative · entry 1

Smith Sherrell · CIK 0001371105 · EVP, Campus Ops & Services

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 185,047

F1 · shares: One third of the restricted stock units approved by the Board of Directors shall vest on each anniversary of the grant date.

SEC source: 0001209191-20-002730 · doc4.xml · derivative · entry 2

Anderson Troy R · CIK 0001789633 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,497

Underlying: Common Stock · 57,497 shares

Expires 2022-01-07

F2 · derivative.exercise_price: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

F2 · derivative.exercise_date: Each performance unit represents a contingent right to receive one share of the Company's common stock, 60% of which vest based on revenue for the fiscal year ending September 30, 2021 and 40% of which vest based on income (loss) from operations for the fiscal year ending September 30, 2021, the sum of which will be adjusted by a compound annual total shareholder return ("TSR") modifier (which modifier may result in the adjustment of the performance units by up to 25% either upward or downward). For purposes of determining the TSR, the change in the price of the Company's common stock is based upon the 30-trading day average closing stock price (i) ending on and including the grant date, and (ii) ending on and including the last day of the Performance Period. The amount represents the maximum number of shares that may be delivered pursuant to the award, which is 187.5% of the target number of shares.

SEC source: 0001209191-20-002730 · doc4.xml · nonDerivative · entry 1

Anderson Troy R · CIK 0001789633 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,665

F1 · shares: One third of the restricted stock units approved by the Board of Directors shall vest on each anniversary of the grant date.